Status:
COMPLETED
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Lead Sponsor:
Bayer
Conditions:
Central Nervous System Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how ...
Detailed Description
Issues on safety will be addressed in Adverse Events section.
Eligibility Criteria
Inclusion
- Patients referred for contrast enhanced MRI of the CNS based on symptoms or previous procedures.
Exclusion
- Patients with acute renal insufficiency
- Patients with severe renal disease
- Patients with any contraindication to magnetic resonance imaging.
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
343 Patients enrolled
Trial Details
Trial ID
NCT00623467
Start Date
December 1 2007
End Date
December 1 2008
Last Update
February 10 2014
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
HOPE Research Institute, LLC
Phoenix, Arizona, United States, 85050
2
Scottsdale Medical Imaging, Ltd.
Scottsdale, Arizona, United States, 85258
3
Radiology Ltd.
Tucson, Arizona, United States, 85711
4
Landmark Imaging Medical Group
Los Angeles, California, United States, 90025